We are just beginning to understand the allosteric regulation of the human cytosolic sulfotransferase (SULTs) family-13 disease-relevant enzymes that regulate the activities of hundreds, if not thousands, of signaling small molecules. SULT1A1, the predominant isoform in adult liver, harbors two noninteracting allosteric sites, each of which binds a different molecular family: the catechins (naturally occurring flavonols) and nonsteroidal antiinflammatory drugs (NSAIDs). Here, we present the structure of an SULT allosteric binding site-the catechin-binding site of SULT1A1 bound to epigallocatechin gallate (EGCG). The allosteric pocket resides in a dynamic region of the protein that enables EGCG to control opening and closure of the enzyme's active-site cap. Furthermore, the structure offers a molecular explanation for the isozyme specificity of EGCG, which is corroborated experimentally. The bindingsite structure was obtained without X-ray crystallography or multidimensional NMR. Instead, a SULT1A1 apoprotein structure was used to guide positioning of a small number of spin-labeled single-Cys mutants that coat the entire enzyme surface with a paramagnetic field of sufficient strength to determine its contribution to the bound ligand's transverse (T 2 ) relaxation from its 1D solution spectrum. EGCG protons were mapped to the protein surface by triangulation using the T 2 values to calculate their distances to a trio of spin-labeled Cys mutants. The final structure was obtained using distance-constrained molecular dynamics docking. This approach, which is readily extensible to other systems, is applicable over a wide range of ligand affinities, requires little protein, avoids the need for isotopically labeled protein, and has no protein molecular weight limitations.
We are just beginning to understand the allosteric regulation of the human cytosolic sulfotransferase (SULTs) family-13 disease-relevant enzymes that regulate the activities of hundreds, if not thousands, of signaling small molecules. SULT1A1, the predominant isoform in adult liver, harbors two noninteracting allosteric sites, each of which binds a different molecular family: the catechins (naturally occurring flavonols) and nonsteroidal antiinflammatory drugs (NSAIDs). Here, we present the structure of an SULT allosteric binding site-the catechin-binding site of SULT1A1 bound to epigallocatechin gallate (EGCG). The allosteric pocket resides in a dynamic region of the protein that enables EGCG to control opening and closure of the enzyme's active-site cap. Furthermore, the structure offers a molecular explanation for the isozyme specificity of EGCG, which is corroborated experimentally. The bindingsite structure was obtained without X-ray crystallography or multidimensional NMR. Instead, a SULT1A1 apoprotein structure was used to guide positioning of a small number of spin-labeled single-Cys mutants that coat the entire enzyme surface with a paramagnetic field of sufficient strength to determine its contribution to the bound ligand's transverse (T 2 ) relaxation from its 1D solution spectrum. EGCG protons were mapped to the protein surface by triangulation using the T 2 values to calculate their distances to a trio of spin-labeled Cys mutants. The final structure was obtained using distance-constrained molecular dynamics docking. This approach, which is readily extensible to other systems, is applicable over a wide range of ligand affinities, requires little protein, avoids the need for isotopically labeled protein, and has no protein molecular weight limitations.
sulfotransferase | structure | NMR | allostery | catechin C ytosolic SULTs regulate disease-relevant process in virtually every tissue in the human body (1) (2) (3) (4) (5) . This small family of broadspecificity enzymes regulates the activities of hundreds, perhaps thousands, of signaling small molecules (e.g., endogenous metabolites, drugs, and other xenobiotics) via regiospecific transfer of the sulfuryl moiety (-SO 3 ) from 3′-phosphoadenosine 5′-phosphosulfate (PAPS) to the hydroxyls and amines of acceptors (1, 6) . Sulfonation often radically alters the interactions of a compound with its target and substantially enhances the target's solubility, transport, and clearance (1, 6, 7) . Through these and other mechanisms, SULTs contribute in critical ways to maintaining signaling homeostasis and neutralizing toxins (6, 8) .
Given their wide-ranging roles in regulating cellular processes, it is perhaps expected that SULTs would have evolved means of communicating with their environments-mechanisms that enable them to read and respond to the small-molecule composition of their "milieu." Early screening studies intimated that SULTs might be subject to small-molecule allosteric control (9, 10) , and recent work confirms this (11) . SULT1A1, the most abundant isoform in adult human liver, harbors at least two physically separate and noninteracting allosteric-binding sites, each of which binds a different complex class of molecules-the catechins (abundant flavonoids in tea and cacao) (9) and nonsteroidal antiinflammatory drugs (NSAIDs) (10) .
EGCG comprises ∼12% of the dry weight of tea leaves (12) and is consumed daily (in near gram quantities) by hundreds of millions of individuals (13) . Like other catechins, EGCG is a low micromolar inhibitor of a number of SULT isoforms (9, 11).
EGCG is, however, unique in that it exhibits particularly high affinity (K i ∼30 nM) for a single isoform, SULT1A1 (9, 11) . To date, there are no published structures of SULT-bound allosteres. The EGCG-binding pocket is promiscuous, and the catechin family is biomorphic; hence, its structure is expected to provide both insight into the molecular basis of catechin regulation and a template that can be used to identify new allosteres and metabolic linkages. Finally, understanding the structural basis of the isoform specificity should provide a "molecular blueprint" for designing allosteres to selectively control SULT biology.
The structure of the EGCG-bound allosteric-binding site of SULT1A1 was obtained without X-ray crystallography or multidimensional NMR. Using a small set of spin-labeled single-Cys mutants selected based on an existing SULT1A1 structure, we demonstrate that the entire surface of SULT1A1 can be coated in a spin-label magnetic field of sufficient strength to use free-ligand proton signals to determine the contribution of the spin label to the T 2 relaxation of bound-ligand protons (14) (15) (16) (17) . Distances between bound-ligand protons and nitroxide labels are calculated from T 2 measurements, and protons are mapped to the protein surface by triangulation using a trio of spin-labeled constructs. A final structure is obtained using position-constrained molecular dynamics docking (16, 18) . This approach is applicable over a wide range of ligand affinities, requires only low protein concentrations, avoids the need for isotopically labeled protein, and, because only the free ligand is being observed, has no protein molecular weight limitations other than the number of spin-labeling sites required to cover the surface of SULT1A1.
Materials and Methods
Materials. The materials and sources used in this study are as follows: DTT, EDTA, 5,5′-dithiobis-2-nitrobenzoic acid, L-glutathione (reduced), 4-hydroxytamoxifen (TAM), imidazole, isopropyl-thio-β-D-galacto-pyranoside (IPTG), LB, lysozyme,
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This article is a PNAS Direct Submission. β-mercaptoethanol, 3-maleimido-PROXYL (2,2,5,5-tetramethyl-1-pyrrolidinyloxy), N-cyclohexylmaleimide, 4-nitrophenol (PNP), pepstatin A, and potassium phosphate were the highest grade available from Sigma. Ampicillin, Hepes, KOH, KCl, MgCl 2 , and PMSF were purchased from Fisher Scientific. Glutathione-and nickel-chelating resins were obtained from GE Healthcare. Competent Escherichia coli [BL21(DE3)] was purchased from Novagen. PAPS was synthesized as previously described (19) and was ≥98% pure as assessed by anion-exchange HPLC.
Computer and Software. Molecular dynamics simulations were performed on a Parallel Quantum Solutions (PQS) QS32-2670C-XS8 computer. PQS Molecular Builder was purchased from Parallel Quantum Solutions Inc. A Genetically Optimized Ligand Docking (GOLD) license was obtained from the Cambridge Crystallographic Data Center. The source code for Groningen Machine for Chemical Simulation (GROMACS) 4.5 was downloaded from www. GROMACS.org under the GROMCAS General Public License.
Methods.
The sulfotransferase1A1 constructs. The SULT1A1-expression plasmid consists of an E. coli codon-optimized SULT1A1-coding region inserted into a triple-tag pGEX-6P expression vector containing an (N-terminal)-His/GST/MBP tag. The Cys-insertion mutants used for regiospecific attachment of maleimide-based labels were constructed as follows: Cys287 and Cys70 (both of which react with DTNB) were replaced with Ser, and three single-Cys mutants were then created by inserting Cys into the nonreactive (C70S and C289S) scaffold at residues G29, E151, and K234. The SULT-cap chimeras were constructed by mutating the wild-type (WT) SULT1A1-coding region as follows: SULT1A3 chimera, F247L; SULT1A2 chimera, P244R and Q245R. All mutagenesis projects began with the SULT1A1-expression plasmid and used standard PCR mutagenesis protocols (20) . Protein purification. SULT expression and purification were performed as described previously (21, 22) . Briefly, transformed E. coli [BL21(DE3)] are grown at 37°C in LB to an OD 600 of ∼0.5. The culture is then chilled in an ice water bath to 17°C before induction with 0.30 mM IPTG. Incubation at 17°C is continued for 18 h before pelleting cells, which are then suspended in lysis buffer (290 μM PMSF, 1.5 μM pepstatin A, 0.10 mg mL −1 lysozyme, 2.0 mM EDTA, 400 mM KCl, 50 mM KPO 4 ; pH 7.5), sonicated, and centrifuged at 4°C; 5.0 mM MgCl 2 is then added to chelate EDTA, and the supernatant is loaded onto a Chelating Sepharose Fast Flow column charged with Ni
2+
. The column is then washed (10 mM imidazole, 400 mM KCl, and 50 mM KPO 4 ; pH 7.5) and enzyme is eluted (250 mM imidazole, 400 mM KCl, and 50 mM KPO 4 ; pH 7.5) onto a Glutathione Sepharose column, which is washed (2.0 mM DTT, 400 mM KCl, and 50 mM KPO 4 ; pH 7.5) before the tagged enzyme is eluted (10 mM reduced glutathione, 2.0 mM DTT, 400 mM KCl, and 100 mM Tris; pH 8.0). The fusion protein is cleaved using PreScission Protease, and the digest is dialyzed (100 mM KCl, 50 mM KPO 4 ; pH 7.5; 4 ± 2°C) and run through a GST column to remove the tag. The protein is then concentrated using an Amicon Ultra Centrifugal Filter (molecular mass cutoff, 10,000 Da). The protein is >95% pure, as judged by SDS/PAGE. Protein concentration is determined by UV absorbance (Ɛ 280 = 53.9 mM −1 cm −1 ). The final protein is flash-frozen and stored at −80°C. Synthesis of 3′-phosphoadenosine 5′-phosphate. Synthesis of 3′-phosphoadenosine 5′-phosphate (PAP) was performed by obtaining PAPS from acid hydrolysis (23) under the following conditions: 0.10 M HCl, pH 1.2, 25 ± 2°C, and 17 h. PAP was purified using anion-exchange chromatography. PAP's purity was assessed at ≥98% using anion-exchange HPLC. Covalent tagging. Labels (N-cyclohexylmaleimide or 3-maleimido-PROXYL) were added in 20:1 over reactive Cys (24) to a solution containing 50 μM enzyme (monomer), 0.50 mM PAP, and 50 mM KPO 4 (pH 7.4; 25 ± 2°C). PAP was added to enhance enzyme stability. Reactions were monitored using DTNB to measure unreacted cysteine and were considered complete when >98% of the cysteine had reacted (∼3 h). Following reaction completion, the reaction mixtures were dialyzed against 0.50 mM PAP and 50 mM KPO 4 
Labeled-construct initial-rate studies. Initial-rate and epigallocatechin gallate (EGCG)-inhibition parameters for the labeled constructs were determined using a previously described PNP assay (11) . Briefly, reactions are initiated by addition of 0.50 mM PAPS (17 × K m ) to a solution containing 0.10 μM enzyme, 10 μM PNP (∼16 × K m ), and 50 mM KPO 4 (pH 7.5; 25 ± 2°C). Reaction progress is monitored by a decrease in PNP absorbance, and K m and V max are determined using progress-curve analysis (6) . EGCG-inhibition studies used identical conditions. K i was obtained from weighted least-squares fitting of initial-rate vs.
[EGCG] data plotted in double-reciprocal space (11) . NMR measurements. Spectra were collected using a Bruker 600-MHz spectrometer equipped with an indirect triple resonance carbon cooled probe at 298 K, at the following EGCG concentrations: 0, 5, 10, 20, and 35 × [active site]. NMRdraw (Lorentzian distribution) (25) was used to obtain peak widths for each of the EGCG protons used in the structure determination. At each EGCG concentration, a 1D proton spectrum was collected from 0 to 14 ppm, using a 0.96-acquisition time and presaturating water pulse. Each spectrum was the time average of 512 scans, with a 1.5-s delay between each scan. Molecular dynamics modeling. SWISS-MODEL (26) was used to create a ligandfree model of SULT1A1 from the SULT1A1·PAP (Protein Data Bank ID code 3G3M) structure (27) , which was missing 23 atoms. The model was protonated at pH 7.4, and energy was minimized in GROMACS (28). GROMAS57 energy-parameter files were created for EGCG, PAPS, and spin-labeled cysteines using Automated Topology Builder (29) . The GROMAS57 field was modified in GROMACS to allow the program to recognize the spin-labeled cysteine as a canonical residue. Spin-labeled cysteines were inserted by replacing residues G29, E151, and K234; PAPS was positioned at the active site using GOLD (30) (31) (32) ; and the system was equilibrated using GROMACS (100-ps increments) to the following simulated condition: 298 K, 50 mM NaCl, and pH 7.4. Once equilibrated, EGCG was positioned randomly in a simulated box of water (52 × 52 × 52 Å) containing the spin-labeled SULT1A1·PAPS construct and then docked in GROMACS using the NMR distance constraints (Positioning EGCG and Results and Discussion). The same structure was obtained each of the 10 times when docking was repeated. Equilibrium binding studies. The binding of ligands to SULT1A1 was monitored via changes in the intrinsic fluorescence of the enzyme (λ ex = 290 nm, λ em = 370 nm). Typical conditions were as follows: ∼25 nM SULT (dimer), 0 or Fig. 1 . The spin-labeled SULT1A1 constructs. The subunits of the SULT1A1 dimer are shown in red and blue. PAP and the acceptor (estradiol) are yellow and beige, respectively. The spin labels (white) are attached at six positions selected to "coat" the dimer in a paramagnetic field of sufficient strength to detect its effects on the solution NMR spectrum of allosteres without compromising the catalytic integrity of the enzyme. The experimental SULT1A1 constructs harbor only a single label per subunit. The semitransparent spheres are centered on the nitroxyl-oxygen of each spin label, and their radii are set to 25 Å-the approximate maximum distance over which ligand/ spin-label interactions can be detected. The design allows the entire surface of the enzyme to be covered in a "detectible field" and allows ligands to be positioned by triangulating their protons from multiple spin labels. 0.50 mM PAP (17 × K d low-affinity ), and 50 mM KPO 4 (pH 7.5; 25 ± 2°C). Titrations were performed in triplicate. Data were averaged and least-squares fit using a model that assumes a single binding site per monomer. EGCG concentration was varied from 0.10 to 20 × K d .
Results and Discussion
The Strategy. Using spin labels to discover where a ligand binds is challenging in that a binding site can lie virtually anywhere on the protein, whereas spin labels are perforce fastened at "fixed" positions by covalent attachment to Cys. Thus, the likelihood that the location of a given binding site will be discovered is determined by the fraction of the enzyme surface that can be "coated" in a spinlabel magnetic field of sufficient strength to affect the linewidth of the ligand's solution spectrum. For a ligand in rapid exchange (14, 16, 18) , proton/spin-label interactions can be detected when the ligand binds within ∼25 Å of a label's insertion point.
SULTs oligomerize into ellipsoid-like dimers whose principal axis dimensions [∼(93 × 42 × 36 Å)] are comparable to the maximum detectable interspin distance (∼25 Å) (33) . Inspection of the SULT1A1 structure, which included molecular dynamics analysis of backbone dynamics, revealed numerous stable (i.e., C α root-meansquare fluctuation, ≤1.0 Å) surface residues that were well isolated from the catalytic machinery and appeared likely to interact extensively with solvent. Among these residues, six were selected for their potential to produce multiple spin-label/ligand interactions regardless of where a ligand binds (notwithstanding the insertion points themselves). The structure of the SULT1A1 dimer with spin labels at these positions is shown in Fig. 1 . The transparent spheres are centered on the oxygen atom of spin-label nitroxyl moiety, and the sphere radius is 25 Å. As can be seen, the entire surface of the enzyme is bathed in a "detectible" magnetic field.
The Constructs. Spin labels were regiospecifically incorporated by covalent attachment at Cys residues inserted via PCR mutagenesis at the desired positions. Prior to site-specific Cys insertion, reactive cysteines in the native enzyme were removed. SULT1A1 contains two native cysteines (C70 and 287). Both react with DTNB and were converted to Ser (34) . Six constructs were prepared from the C70S, C287S construct, each with Cys inserted at a different target position in the nonreactive scaffold. Spin labels were then covalently attached (Methods), and the catalytic integrity of each labeled mutant was tested by determining its initialrate parameters: k cat , K m , and K i for EGCG inhibition. The results, compiled in Table 1 , reveal that the labeled-mutant parameters are nearly identical to those of the WT enzyme.
The Method. The effects of an unpaired spin-label electron on the NMR linewidth of a protein-bound ligand-nucleus are well understood (24, 35, 36) . The distance dependence of these effects have been used extensively to position ligands relative to spin labels covalently attached to proteins (14, 18, 37) . The distance between an unpaired electron in a covalently attached spin label and a proton in a protein-bound ligand is calculated from the contribution of the electron to the transverse relaxation rate of the proton, R 2 , using Eq. 1 (17, 37):
where r is the interspin distance, μ o is the permeability of a vacuum, γ is the proton gyromagnetic ratio, g is the electron g-factor, μ B is the magnetic moment of the free electron, S is the electron spin quantum number, τ c is the rotational correlation time of the protein, and ω is the Larmor frequency of the proton. Transverse relaxation rates are calculated from NMR linewidths, which, for bound ligands, are typically too broad to measure directly. However, when the frequency of ligand exchange between bulk solution and the protein is comparable to or greater than the difference in the Larmor frequency between the bound and free proton, the effects of the protein on linewidth can be detected in the ligand's solution spectrum (16, 18) , Fig. 2 A and B . The resulting bulk-solution linewidths provide observed transverse relaxation rates, R 2 obs , which depend linearly on the fraction of bound ligand, F B , according to Eq. 2, where R 2B and R 2F are the transverse-relaxation rates for bound and free protons, and R 2ex is the chemical-exchange contribution to the relaxation.
[2]
In spin-labeled (paramagnetic) constructs, the bound-ligand proton relaxation is affected by fluctuating magnetic fields from both the unpaired electron and protein. To obtain the contribution of the electron, which is used to calculate distances, these two contributions must be separated experimentally. To do so, R 2 obs vs. F B plots (Eq. 2) are created using the spin-labeled protein and a control (diamagnetic) construct in which the spinlabel PROXYL moiety is replaced by a cyclohexyl group (24) (Methods). The contribution of the unpaired electron is obtained by subtracting the slopes of the two plots. Representative R 2 obs vs. F B plots are shown in Fig. 2C .
Positioning EGCG. Positioning an EGCG proton on the surface of the enzyme is accomplished by triangulating its distance from three spatially well separated spin labels. Orienting the molecule relative to the surface requires triangulating multiple ligand nuclei that span the body of the molecule. EGCG was positioned and oriented using protons in each of its four rings ( Fig. 2A) . To identify the optimal Cys constructs for the study, each of the six spin-labeled constructs was tested for its effects on the linewidths of the EGCG solution spectrum. The G29, E155, and K234 constructs were chosen for the distance measurements.
Having selected the EGCG protons and Cys constructs, 24 R 2 obs vs. F B plots were constructed: a dia-and paramagnetic pair of plots for each of the 12 proton/enzyme construct pairs. The plots are shown in Fig. 2C and Fig. S1 . The contribution of the unpaired electron spin to the transverse relaxation of the bound EGCG protons was obtained by subtracting the slopes of the pairs and used to calculate proton-to-spin-label distances, which are compiled, along with their error, in Table 2 . The NMR distance measurements allow each proton to be positioned at the center of an "error ellipsoid" whose principal axes are given by the SE of the measurement, ±∼4 Å, and the final structure is obtained by refining the NMR-determined position using all atom molecular dynamics.
Refining the Structure. The NMR-determined distances provide an initial ligand position that is subsequently refined using molecular dynamics docking (GROMACS) under conditions where ligand motion is constrained by the distance measurements (28, 38) . Constraints are embedded in the simulations by defining an ellipsoid whose center is the point of intersection of the three NMRdistance vectors that position the proton and whose principal axes lengths are given by the SEs (± 1 σ) of the measurements. If any part of a proton's van der Walls surface lies outside its ellipsoid, a restoring force (50 kj mol
) that drives the proton toward the ellipsoid center is applied using distance_restraints in GROMACS (28, 38) ; the restoring force inside the ellipsoid is zero. As is appropriate for positioning based on NMR spin-spin interaction measurements (17, 37, 39) , distance_restraints was parameterized to use (1/r 6 )-weighted, time-averaged distance restrains. The motions of all four of the EGCG protons were constrained simultaneously by their distances to the three spin labels. Identical structures were achieved at equilibrium each of the 10 times docking was simulated, and the structure did not change once the distance constraints were removed.
It is notable that using the SULT1A1 apostructure as a docking start point biases the outcome toward that structure. It is possible that a more stable structure exists but is inaccessible to simulation. Table 3 . (B) Binding of TAM to WT and F247L SULT1A1. Conditions and data analysis were as described for A, except the EGCG was present and saturating (20 μM WT: 500 × K d ; chimeras: 28 × K d ) and TAM was the titrant. The TAM dissociation constants are listed in Table 4 .
The likelihood that such structures exit is constrained by the fact that they must conform to all NMR distance measurements and be consistent with site-directed mutagenesis studies designed to validate them (The Molecular Basis of Isozyme Specificity).
The Final Structure. SULT1A1 harbors a conserved ∼30-residue active-site cap that opens and closes in response to nucleotide. Nucleotide binding closes the cap, which encapsulates the nucleotide and creates a pore through which acceptors must pass to access the active site. The cap is depicted in gold in Fig. 3A , and the pore is indicated by the four colored segments that coalesce to form the active-site entrance. The lower lip contacts acceptors and screens them for "high-efficiency" characteristics (40) that elicit from the lip a clamp-like structure that binds the substrate tightly and positions it for rapid transfer chemistry. The efficiencies (k cat /K m ) of such substrates are three to four orders of magnitude higher than those of typical 1A1 acceptors.
The EGCG binding pocket lies at an interface between the cap and lower lip. EGCG does not protrude into the active site (Fig.  3B) , which is consistent with the fact that the affinities of acceptors small enough to pass through the pore are not affected by its presence (22) . The cap closes 18-fold more "tightly" when EGCG is bound (11, 41) ; indeed, the enhanced trapping of nucleotide that results from this tighter binding appears to be the mechanistic basis of EGCG inhibition (41) . Here, we see the structural basis for this inhibition-the rings of EGCG are entwined with those of the lip and cap (Fig. 3C ). It appears EGCG acts as molecular "glue" to inhibit separation of the lip and cap, which, in turn, impedes nucleotide release.
The Molecular Basis of Isozyme Specificity. EGCG is a far more potent inhibitor of SULT1A1 than it is of the closely related homologs 1A3 and 1A2 [∼20-fold on a K i basis (9)]. These isoforms are, respectively, 93 and 96% identical and 98 and 99% conserved relative to 1A1. Although the positions of the residue differences among the isoforms are scattered across the 1A1 scaffold, all three differ at a single point of contact with EGCG-a small cap-region whose rings are intercalated into those of EGCG. We surmised that these interactions were the basis for the isoform specificity of EGCG and tested this hypothesis by "swapping" the cap of 1A1 for those of 1A3 and 1A2 and determining the behavior of the chimeras toward EGCG. The 1A3 and 1A2 caps differ very slightly from that of 1A1-one position (F247) in 1A3 and two (P244 and Q245) in 1A2 (Fig. 3C ). Chimeras were constructed by converting the 1A1 cap into its 1A2 and 1A3 counterparts.
The effects of the mutations on the affinity of EGCG were determined in equilibrium-binding studies that monitor binding through changes in the enzyme's intrinsic fluorescence. EGCG binds 18-fold more tightly to the PAP-saturated 1A1 dimer than to the unliganded enzyme, whose caps do not close when EGCG binds (9) . The structure predicts that the chimera mutations will weaken the EGCG/cap interactions. If these mutations weaken only interactions between the cap and EGCG, their maximum effect will occur at the point that the cap no longer closes. If so, the affinity of EGCG for the PAP-saturated chimeras should decrease to that for enzyme forms whose caps do not close when EGCG binds, which is precisely what is observed. The affinity of EGCG for the PAP-saturated chimeras is, within error, 18-fold less than that for the native, saturated enzyme and equal to EGCG's affinity for unliganded WT SULT1A1 (Fig. 4A and Table 3 ).
To confirm that the 18-fold weakening of EGCG binding to the PAP-saturated chimeras is in fact due an inability of the cap to close, the open/closed status of the cap was determined in these complexes. Cap status was assessed using acceptors that are too large to pass through the pore when the cap is closed. The affinities of such acceptors are weakened by ligands that close the cap by a factor that is essentially equal to the change in the cap-closure equilibrium constant caused by the ligand (22) . TAM is such an acceptor and was used previously to determine the EGCG dependence of the open/ closed status of WT SULT1A1 (42) . The affinity of TAM for the E·PAP complex of the chimeras was determined in the presence and absence of saturating EGCG (20 × K d ) and compared with that of WT. As can be seen in Fig. 4B and Table 4 , the affinities of TAM for the WT and chimeras are virtually identical in the absence of EGCG, and addition of EGCG weakens (18-fold) the affinity only for the WT enzyme. Hence, the caps of the chimeras remain open in the presence of saturating nucleotide and EGCG.
The "unlatching" of the cap that occurs when interactions between rings of the cap and EGCG are disrupted and the concomitant loss of EGCG's specificity for 1A1 reveal that these interactions determine isoform specificity. The caps of SULT isoforms are unique at the points of contact between EGCG and the 1A1 cap; thus, it may be possible to modify the EGCG scaffold such that it "closes" only the cap of a chosen isoform, that is, to create isoform-specific allosteric inhibitors. There are numerous disease-relevant conditions in which such allosteres could prove valuable in disease prevention and management-SULT1E1 is up-regulated ∼17-fold during adipogenesis and is thought to be a druggable enzyme target for treating obesity (5); individuals genetically disposed toward high-level SULT1A1 expression show far higher incidence of prostate cancer, particularly those whose diets are enriched in SULT1A1-activated procarcinogens (43); a nasally inhaled SULT1A3 inhibitor is predicted to up-regulate dopamine activity in brain (44) and could prove useful in treating neurocognitive diseases, including Parkinson's disease (45, 46) , addiction (47) , and obsessive compulsive disorder (4); finally, SULT1A1 expression in monocyte-derived macrophages is tightly, positively correlated with HIV replication (48) .
Conclusions
The structure of the catechin allosteric-binding site of SULT1A1 has been determined using a spin-label triangulation method. The technique is expected to translate well to other systems and, in particular, to other SULT isoforms, where SULT1A1 will be used to obtain structures of the binding sites of other putative SULT allosteres, which include the potent inhibition of SULT1A1 by NSAIDs (10, 11) ; the allosteric regulation of SULT2A1 by celecoxib, an FDA-approved anticancer drug that changes the substrate specificity of the enzyme (49) ; and the potent inhibition of SULT1E1 by polychlorinated hydroxyl-bisphenols (OH-PCBs)-the putative basis for the endocrine disruptions caused by these environmental toxins (50, 51) . Beyond using the method in the current study to decipher how, at the molecular level, allosteres control SULT catalytic function lies the important issue of how such insights might be used to deepen our understanding of SULT biology. It is important to realize that these sites, like the enzymes themselves, are promiscuous in that they bind classes of structurally related compounds-a seemingly cunning strategy for embedding broadbased sensitivity to the metabolome. The NSAID (52) , catechin (9) , and OH-PCBs (53) families are composed of highly biomorphic compounds whose allosteric properties were discovered serendipitously during classic inhibition studies. There seems little doubt that related endogenous metabolites will also prove to be allosteres, each of which will extend the metabolic network of SULT interactions. Ultimately, with structures in hand, it may be possible to build allosteres that can enhance or diminish SULT reactivity in an isoform-specific fashion and be used to probe and control SULT biology.
